Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Availability and costs of medicines for the treatment of tuberculosis in Europe
Avtorji:ID Günther, Gunar (Avtor)
ID Guglielmetti, Lorenzo (Avtor)
ID Leu, Claude (Avtor)
ID Lange, Christoph (Avtor)
ID Leth, Frank van (Avtor)
ID Svetina, Petra, Klinika Golnik (Sodelavec pri raziskavi)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://www.clinicalmicrobiologyandinfection.com/action/showPdf?pii=S1198-743X%2822%2900394-9
 
Jezik:Angleški jezik
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Objectives. To evaluate the access to comprehensive diagnostics and novel anti-tuberculosis medicines in European countries. Methods. We investigated access to genotypic and phenotypic M. tuberculosis drug susceptibility testing, availability of anti-tuberculosis drugs and calculated cost of drugs and treatment regimens at major tuberculosis treatment centers in countries of the World Health Organization (WHO) European region where rates of drug-resistant tuberculosis are highest among all WHO regions. Results are stratified by middle-income and high-income countries. Results. Overall, 43 treatment centers in 43 countries participated in the study. For WHO Group A drugs, the frequency of countries with availability of phenotypic drug susceptibility testing was as follows: 30/40 (75%) for levofloxacin, 33/40 (82%) for moxifloxacin, 19/40 (48%) for bedaquiline and 29/40 (72%) for linezolid, respectively. Overall, 36/43 (84%) and 24/43 (56%) of countries had access to bedaquiline and delamanid, while only 6/43 (14%) had access to rifapentine. Treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was only available in 17/43 (40%) of the countries. Median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for six months) and extensively drug-resistant tuberculosis (including bedaquiline, delamanid and a carbapenem) were € 44 (min-max € 15-152), € 764 (min-max € 542-15152) and € 8709 (min-max € 7965-11759) in middle-income countries (n=12), and € 280 (min-max-€78-1084), € 29765 (min-max 11116-40584), € 217591 (min-max € 82827-320146) in high-income countries (n=29). Conclusion. In countries of the WHO Europe Region there is a widespread lack of drug susceptibility testing capacity to new and re-purposed anti-tuberculosis drugs, lack of access to essential medications in several countries and high treatment cost for drug-resistant tuberculosis.
Ključne besede:tuberculosis - drug therapy, Mycobacterium tuberculosis - drug therapy, health care costs - drug therapy, Europe
Datum sprejetja članka:28.07.2022
Datum objave:09.08.2022
Kraj izida:Velika Britanija
Založnik:Elsevier
Leto izida:2022
Št. strani:str. 1-29
Številčenje:Vol. 28, št.
PID:20.500.12556/DiRROS-15410 Novo okno
UDK:616-002
ISSN pri članku:1469-0691
DOI:10.1016/j.cmi.2022.07.026 Novo okno
COBISS.SI-ID:119066371 Novo okno
Avtorske pravice:© 2022 The Author(s).
Opomba:Nasl. z nasl. zaslona; Članica raziskovalne skupine TBNET iz Slovenije: Petra Svetina; Opis vira z dne 24. 8. 2022;
Datum objave v DiRROS:31.08.2022
Število ogledov:667
Število prenosov:137
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Clinical microbiology and infection
Skrajšan naslov:Clin. microbiol. infect.
Založnik:Blackwell Science
ISSN:1469-0691
COBISS.SI-ID:58958081 Novo okno

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.
Začetek licenciranja:09.08.2022

Sekundarni jezik

Jezik:Ni določen
Naslov:Cost of TB in Europe
Ključne besede:tuberkuloza - terapija z zdravili, Mycobacterium tuberculosis - terapija z zdravili, stroški zdravstvene oskrbe - terapija z zdravili, Evropa


Nazaj